



تاریخ دریافت ۸۳/۰۹/۱۱ تاریخ پذیرش ۸۳/۱۲/۱۲

(± /) (± /) :
/ ± / / ± / / ± / / ± /
/ ± / / ± / / ± / (p < /)
/ ± / (p < /) / ± /
/ () :
/ () :
/ () :

()

HBs Ag ()

HCV UGT¹

(LDH ALP ALT AST) ()

()

(CV: < / %:) ()

/ / / ()

SPSS;)

(Chicago version, 11.5 p

ROC

/ p ()

()

()

/ ± / (± /) / ± /

/ ± / / ± /

/ mg/dl



/ ± / / ± /


(p < /)

⁴ Diazo
⁵ Sensivity
⁶ Specificity

¹ Bilirubin Uridine Diphosphate Glucuronoasyltransferase
² Incomplete
³ Fasting test

/ ± / / ± /
(% / % /) (p < /)
%) / (%





Indirect bil.after test (CI, 95%)
 Area under the ROC curve = 1(1-1)

T.bil after test (CI, 95%) Sig.
 0.979(0.850-0.992) P=0.431

Cutt_offs for total Bilirubin after rifampin test:

| Criterion | Sens. (95% C.I.) | Spec. (95% C.I.) | +PV | -PV |
|-----------|------------------|------------------|-----|-----|
| > / | /(/) | /(/) | / | / |
| > / | /(/) | /(/) | / | / |
| > / * | /(/) | /(/) | / | / |
| > / | /(/) | /(/) | / | / |
| > / | /(/) | /(/) | / | / |
| > / | /(/) | /(/) | / | / |
| > / | /(/) | /(/) | / | / |
| > / | /(/) | /(/) | / | / |

Cutt_offs for indirect Bilirubin after rifampin test:

| Criterion | Sens. (95% C.I.) | Spec. (95% C.I.) | +PV | -PV |
|-----------|------------------|------------------|-----|-----|
| > | /(/) | /(/) | / | |
| > / | /(/) | /(/) | / | / |
| > / * | /(/) | /(/) | / | / |
| > / | /(/ v) | /(/) | / | / |
| > / | /(/) | /(/) | / | / |
| > / | /(v /) | /(/) | / | / |
| > | /(/) | /(/) | / | / |

(ROC curve)

:

References

1. Watson KJ, Gollan JL: Gilbert's syndrome. *Bailliere's Clin Gastroenterol*, 1989; 3: 337-355.
2. Le Bihan-Levaufre B, Francoual J, Chalas J, Trioche P, Capel L, Lindenbaum A, et al: Genetic incidence of Gilbert's syndrome in France. *Gastroenterol Clin Biol (France)*, 2001; 25: 557-558.
3. Bosma PJ: Inherited disorder of bilirubin metabolism. *J Hepatol*, 2003; 38: 107-117.
4. Bosma PJ, Chowdhury JR, Bakker C, Gantla S, de Boer A, Oostra BA, et al: The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. *N Engl J Med*, 1995; 333: 1171-1175.
5. Peters WH, te Morsche RH, Roelofs HM: Combined polymorphisms in UDP-glucuronosyltransferases 1A1 and 1A6:

- implications for patients with Gilbert's syndrome. *J Hepatol*, 2003; 38: 3-8.
6. Borlak J, Thum T, Landt O, Erb K, Hermann R: Molecular diagnosis of a familial non hemolytic hyperbilirubinemia (Gilbert's syndrome) in healthy subjects. *Hepatology*, 2000; 32: 792-795.
 7. Mendoza Hernandez JL, Garcia Paredes J, Larrubia Marfil JR, Casimiro Peytavi C, Diaz-Rubio M: Diagnosis of Gilbert's syndrome: current status of the fasting test: Review of the literature. *Ann Med Interna*, 1997; 14: 57-61.
 8. Dickey W, McAleer JJ, Callender ME: The nicotinic acid provocation test and unconjugated hyperbilirubinaemia. *Ulster Med J*, 1991; 60: 49-52.
 9. Koduri PR: Genetic testing for Gilbert's syndrome. *Int J Clin Pract*, 2001; 55: 81-83.
 10. Gorski JC, Vannaprasaht S, Hamman MA, Ambrosius WT, Bruce MA, Haehner-Daniels B, et al: The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity. *Clin Pharmacol Ther*, 2003; 74: 275-287.
 11. Murthy GD, Byron D, Shoemaker D, Visweswaraiiah H, Pasquale D: The utility of rifampin in diagnosing Gilbert's syndrome. *Am J Gastroenterol*, 2001; 96: 1150-1154.
 12. Gentile S, Marmo R, Persico M, Bronzino P, Coltorti M: Plasma clearance of nicotinic acid and rifamycin-SV, and their interaction in Gilbert's syndrome: application of a compartmental model. *Hepatogastroenterology*, 1984; 31: 72-75.
 13. Erdil A, Kadayifci A, Ates Y, Bagci S, Uygun A, Dagalb K: Rifampicin test in the diagnosis of Gilbert's syndrome. *Int J Clin Pract*, 2001; 55: 81-83.
 14. Velilla Alcubilla JP, Garcia Mauriz E, Martinez Bruna MS, Abinzano ML, Martinez Velasco MC: The rifampicin test in the diagnosis of Gilbert syndrome (Spanish). *Aten Primaria*, 1993; 11: 40-42.
 15. Thompson R: Genetic transmission of Gilbert's syndrome In: Okolicsanyi L, editor: *Familial hyperbilirubinemia*. Chichester, John Wiley, 1981: 91-97.
 16. Radu P, Atsmon J: Gilbert's syndrome - clinical and pharmacological implications. *Isr Med Assoc J*, 2001; 3: 593-598.
 17. Noguerado Asensio A, Mearineearine Manrique F, Escudero Sereno V, Hidalgo Fernandez S, Garcia Monzon C, Pajares Garcia JM: Gilbert's syndrome: comparative study of fasting and rifampicin as diagnostic tests. *Rev Esp Enferm Apar Dig*, 1986; 69: 133-135.
 18. Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivisto KT: Pharmacokinetic interactions with rifampicin: clinical relevance. *Clin Pharmacokinetics*, 2003; 42: 819-850.